Interventions for cellulitis and erysipelas

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 12, 2010, Pages

  Kilburn, Sally A ^a   Featherstone, Peter ^a   Higgins, Bernie ^a   Brindle, Richard ^b  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b PORTSMOUTH HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN DERIVATIVE; MACROLIDE; PENICILLIN DERIVATIVE;

CELLULITIS; ERYSIPELAS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADMINISTRATION, ORAL; CELLULITIS; CEPHALOSPORINS; ERYSIPELAS; HUMANS; INJECTIONS, INTRAVENOUS; MACROLIDES; PENICILLINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77954977969     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004299.pub2     Document Type: Review

References (149)

1. Bergkvist PI, Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: A randomized, double blind, placebo-controlled study. Scandinavian Journal of Infectious Diseases 1997;29(4):377-82. x-wiley/crsRef/15497102
2. Bernard P, Plantin P, Roger H, Sassolas B, Villaret E, Legrain V, et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: A comparative study. British Journal of Dermatology 1992;127(2):155-9. x-wiley/crsRef/15497104
3. Bernard P, Chosidow O, Vaillant L. Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: Randomised, non-inferiority, open trial. BMJ 2002;325(7369):864-9. x-wiley/crsRef/15497106
4. Bucko AD, Hunt BJ, Kidd SL, Hom R. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clinical Therapeutics 2002;24(7):1134-47. x-wiley/crsRef/15497108
5. Bucko AD, Hunt BJ, Kidd SL, Hom R. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clinical Therapeutics 2002;24(7):1134-47. x-wiley/crsRef/15497110
6. Chan JC. Ampicillin/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology. Advances in Therapy 1995;12(2):139-46. x-wiley/crsRef/15497112
7. Daniel R. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. European Azithromycin Study Group. Journal of International Medical Research 1991;19(6):433-45. x-wiley/crsRef/15497114
8. Daniel R. Azithromycin, erythromycin and cloxacillin in the treatment of infections of skin and associated soft tissues. European Azithromycin Study Group. Journal of International Medical Research 1991;19(6):433-45. x-wiley/crsRef/15497116
9. DiMattia AF, Sexton MJ, Smialowicz CR, Knapp WH Jr. Efficacy of two dosage schedules of cephalexin in dermatologic infections. Journal of Family Practice 1981;12(4):649-52. x-wiley/crsRef/15497118
10. Fabian TC, File TM Jr, Embil JM, Krige JEJ, Klein S, Rose A, et al. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: Results of a multicenter, randomized, double blind comparative study. Surgical Infections 2005;6(3):269-82. x-wiley/crsRef/15497120
11. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. International Journal of Antimicrobial Agents 2005;26(5):357-65. x-wiley/crsRef/15497122
12. Grayson ML, McDonald M, Gibson K, Athan E, Munckhof WJ, Paull P, et al. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clinical Infectious Diseases 2002;34(11):1440-8. x-wiley/crsRef/15497124
13. Grayson ML, McDonald M, Gibson K, Athan E, Munckhof WJ, Paull P, et al. Once-daily IV cefazolin 2g plus oral probenecid 1g is equivalent to once-daily IV ceftriaxone 1g plus oral placebo for the hospital-in-the-home treatment of cellulitis. Internal Medicine Journal 2001;31:A13. x-wiley/crsRef/15497125
14. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Archives of Internal Medicine 2004;164(15):1669-74. x-wiley/crsRef/15497127
15. Iannini PB, Kunkel MJ, Link ASJ, Simons WJ, Lee TJ, Tight RR. Multicenter comparison of cefonicid and cefazolin in hospitalized patients with skin and soft tissue infections. Advances in Therapy 1985;2(5):214-24. x-wiley/crsRef/15497129
16. Johnson S, Leak K, Singh S, Tan P, Pillay W, Cuschieri R. Can cycloidal vibration plus standard treatment reduce lower limb cellulitis treatment times? Journal of Wound Care 2007;16(4):166-9. x-wiley/crsRef/15497131
17. Kiani R. Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections. European Journal of Clinical Microbiology & Infectious Diseases 1991;10(10):880-4. x-wiley/crsRef/15497133
18. Leman P, Mukherjee D. Flucloxacillin alone or combined with benzylpenicillin to treat lower limb cellulitis: A randomised controlled trial. Emergency Medicine Journal 2005;22(5):342-46. x-wiley/crsRef/15497135
19. Rao B, See RC, Chuah Sk, Bansal MB, Lou MA, Thadepalli H. Ticarcillin plus calvulanic acid versus moxalactam in the treatment of skin and soft tissue infections. The American Journal of Medicine 1985;79 Suppl 2(5):126-9. x-wiley/crsRef/15497137
20. Sachs MK, Pilgrim C. Ampicillin/sulbactam compared with cefazolin or cefoxitin for the treatment of skin and skin structure infections. Drug Investigation 1990;2(3):173-83. x-wiley/crsRef/15497139
21. Schwartz R, Das-Young LR, Ramirez-Ronda C, Frank E. Current and future management of serious skin and skin-structure infections. American Journal of Medicine 1996;100(6A):90S-5S. x-wiley/crsRef/15497141
22. Tack KJ, Littlejohn TW, Mailloux G, Wolf MM, Keyserling CH. Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group. Clinical Therapeutics 1998;20(2):244-56. x-wiley/crsRef/15497143
23. Tarshis GA, Miskin BM, Jones TM, Champlin J, Wingert KJ, Breen JD, et al. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: Double blind, multicenter, randomized study. Antimicrobial Agents and Chemotherapy 2001;45(8):2358-62. x-wiley/crsRef/15497145
24. Vinen J, Hudson B, Chan B, Fernandes C. A randomised comparative study of once-daily ceftriaxone and 6-hourly flucloxacillin in the treatment of moderate to severe cellulitis. Clinical efficacy, safety and pharmacoeconomic implications. Clinical Drug Investigation 1996;12(5):221-5. x-wiley/crsRef/15497147
25. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch, Linezolid study group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrobial Agents and Chemotherapy 2005;49(6):2260-6. x-wiley/crsRef/15497149
26. Zeglaoui F, Dziri C, Mokhtar I, Ezzine N, Kharfi M, Zghal M, et al. Intramuscular bipenicillin vs. intravenous penicillin in the treatment of erysipelas in adults: Randomized controlled study. Journal of the European Academy of Dermatology and Venereology (JEADV) 2004;18(4):426-8. x-wiley/crsRef/15497151
27. Agache P, Amblard P, Moulin G, Barrière H, Texier L, Beylot C, et al. Roxithromycin in skin and soft tissue infections. Journal of Antimicrobial Chemotherapy 1987;20 Suppl B:153-6. x-wiley/crsRef/15497153
28. Agache P, Amblard P, Moulin G, Barrière H, Texier L, Beylot C, et al. Roxithromycin in skin and soft tissue infections. Journal of Antimicrobial Chemotherapy 1987;20 Suppl B:153-6. x-wiley/crsRef/15497155
29. Amaya-Tapia G, Andrade-Villanueva J, Flores-Glaxiola A, Aguirre-Avalos G, Morfin-Otero R, Esparza-Ahumada S. Safety and efficacy of lomefloxacin and cefaclor in the treatment of skin and skin structure infections. International Journal of Antimicrobial Agents 1992;2(1):55-60. x-wiley/crsRef/15497157
30. Amaya-Tapia G, Aguirre-Avalos G, Andrade-Villanueva J, Peredo-González G, Morfín-Otero R, Esparza-Ahumada S, et al. Once-daily azithromycin in the treatment of adult skin and skin-structure infections. Journal of Antimicrobial Chemotherapy 1993;31 Suppl E:129-35. x-wiley/crsRef/15497159
31. Arata J, Yamamoto Y, Tamaki H, Ookawara A, Fukaya T, Ishibashi Y, et al. Double-blind study of lomefloxacin vs. norfloxacin in the treatment of skin and soft tissue infections. Chemotherapy 1989;37(4):482-503. x-wiley/crsRef/15497161
32. Arata J, Akiyama H, Abe Y, Ishibashi Y, Takehara K, Tsuchida T, et al. A double-blind comparative study of S-1108 and cefaclor in skin and skin structure infections. Chemotherapy 1994;42(3):326-45. x-wiley/crsRef/15497163
33. Arata J, Kanzaki H, Abe Y, Torigoe R, Ohkawara A, Yamanaka K, et al. A multicenter, double-blind, double-placebo comparative study of SY 5555 versus cefaclor in the treatment of skin and skin structure infections. Chemotherapy 1994;42(6):740-60. x-wiley/crsRef/15497165
34. Arata J, Torigoe R, Ohkawara A, et al. A multicenter, double-blind, double placebo clinical trial of azithromycin versus cefaclor in the treatment of skin and skin structure infections. Japanese Journal of Chemotherapy 1995;43(11):1069-87. x-wiley/crsRef/15497167
35. Azimi PH, Barson WJ, Janner D, Swanson R. Efficacy and safety of ampicillin/sulbactam and cefuroxime in the treatment of serious skin and skin structure infections in pediatric patients. UNASYN Pediatric Study Group. The Pediatric Infectious Disease Journal 1999;18(7):609-13. x-wiley/crsRef/15497169
36. Ballantyne F. A comprehensive study of cefadroxil and cephalexin in the treatment of soft tissue infections. Journal of International Medical Research 1980;8 Suppl 1:70-4. x-wiley/crsRef/15497171
37. Ballantyne FN. Comparative efficacy of cefadroxil and cefaclor in the treatment of skin and soft-tissue infections. Clinical Therapeutics 1985;7(4):487-91. x-wiley/crsRef/15497173
38. Bechard DL, Hawkins SH, Sutherland SC. Comparative evaluation of cefmenoxime versus cefoxitin in serious infections. American Journal of Medicine 1984;77(6A):13-6. x-wiley/crsRef/15497175
39. Bergkvist PI, Sjobeck K. Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: A 1-year follow-up. Scandinavian Journal of Infectious Diseases 1998;30(2):206-7. x-wiley/crsRef/15497177
40. Blaszczyk-Kostanecka M, Dobozy A, Dominguez-Soto L, Guerrero R, Hunyadi J, Lopera J, et al. Comparison of two regimens of oral clindamycin versus dicloxacillin in the treatment of mild-to-moderate skin and soft-tissue infections. Current Therapeutic Research - Clinical and Experimental 1998;59(6):341-53. x-wiley/crsRef/15497179
41. Bradsher RW Jr, Snow RM. Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. American Journal of Medicine 1984;77(4C):63-7. x-wiley/crsRef/15497181
42. Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrobial Agents and Chemotherapy 2005;49(11):4658-66. x-wiley/crsRef/15497183
43. Brown G, Chamberlain R, Goulding J, Clarke A. Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. Journal of Emergency Medicine 1996;14(5):547-51. x-wiley/crsRef/15497185
44. Browning AK. The efficacy of twice daily cephalexin. Pharmatherapeutica 1981;2(9):559-64. x-wiley/crsRef/15497187
45. Carbon C. Prospective randomized phase II study of intravenous cefpirome 1g or 2g bd in the treatment of hospitalized patients with different infections. Cefpirome Study Group. Journal of Antimicrobial Chemotherapy 1992;29 Suppl A:87-94. x-wiley/crsRef/15497189
46. Carbon C. Overview of the efficacy of isepamicin in the adult core clinical trial programme. Journal of Chemotherapy 1995;7 Suppl 2:79-85. x-wiley/crsRef/15497191
47. Carr WD, Wall AR, Georgala-Zervogiani S, Stratigos J, Gouriotou K. Fusidic acid tablets in patients with skin and soft-tissue infection: A dose-finding study. European Journal of Clinical Research 1994;5:87-95. x-wiley/crsRef/15497193
48. Chiodini PL, Toop MJ, Odugbesan O, Gilbert J, Farrell ID, Barnett AH, et al. Sulbactam/ampicillin: Effects on glucose metabolism in diabetics with soft tissue infection. Journal of Antimicrobial Chemotherapy 1985;16(5):643-7. x-wiley/crsRef/15497195
49. Chirurgi VA, Edelstein H, Oster SE, Karp R, Cassano KB, Aiken S, et al. Randomized comparison trial of teicoplanin i.v., teicoplanin i.m., and cefazolin therapy for skin and soft tissue infections caused by gram-positive bacteria. Southern Medical Journal 1994;87(9):875-80. x-wiley/crsRef/15497197
50. Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. Journal of Antimicrobial Chemotherapy 1996;38(3):523-37. x-wiley/crsRef/15497199
51. Colin M, Avon P. Comparative double-blind evaluation of a new topical antibacterial agent, mupirocin, compared with placebo in the treatment of skin and soft tissue infections [Evaluation comparative double aveugle du nouvel agent antibacterien topique, la mupirocine, par rapport a un placebo dans le traitement des infections de la peau et des tissus mous]. Pharmatherapeutica 1988;5(3):198-203. x-wiley/crsRef/15497201
52. Daly JS, Worthington MG, Andrews RJ, Brown RB, Schwartz R, Sexton DJ. Randomized, double-blind trial of cefonicid and nafcillin in the treatment of skin and skin structure infections. Antimicrobial Agents & Chemotherapy 1990;34(4):654-6. x-wiley/crsRef/15497203
53. Derriennic M, Escande JP. Dirithromycin in the treatment of skin and skin structure infections. Journal of Antimicrobial Chemotherapy 1993;31 Suppl C:159-68. x-wiley/crsRef/15497205
54. Echols R, Coulter H. Efficacy and safety of IV ciprofloxacin versus standard antimicrobial therapy in the treatment of selected tissue infections. Infections in Medicine 1994;11(6):461-9. x-wiley/crsRef/15497207
55. Edelstein H, Oster SE, Chirurgi VA, Karp RA, Cassano KB, McCabe RE. Intravenous or intramuscular teicoplanin once daily for skin and soft-tissue infections. DICP: the annals of pharmacotherapy 1991;25(9):914-8. x-wiley/crsRef/15497209
56. Eron LJ, Park CH, Hixon DL, Goldenberg RI, Poretz DM. Ceftriaxone therapy of bone and soft tissue infections in hospital and outpatient settings. Antimicrobial Agents & Chemotherapy 1983;23(5):731-7. x-wiley/crsRef/15497211
57. Fass RJ, Plouffe JF, Russell JA. Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. American Journal of Medicine 1989;87(5A):164S-8S. x-wiley/crsRef/15497213
58. File TM Jr, Tan JS. Ticarcillin-clavulanate therapy for bacterial skin and soft tissue infections. Reviews of Infectious Diseases 1991;13 Suppl 9:S733-6. x-wiley/crsRef/15497215
59. Fleisher GR, Wilmott CM, Campos JM. Amoxicillin combined with clavulanic acid for the treatment of soft tissue infections in children. Antimicrobial Agents & Chemotherapy 1983;24(5):679-81. x-wiley/crsRef/15497217
60. Frank E, Phillips SL, Gupta T, Bavishi N, Casey KK. Treatment of skin and soft tissue infections: A comparative study of cefmetazole and cefoxitin. Journal of Antimicrobial Chemotherapy 1989;23 Suppl D:55-60. x-wiley/crsRef/15497219
61. Fujita K, Takahashi H, Mizoguchi A, Takeshima M, Sasaki J, Nonami E, et al. Clinical evaluation of lenampicillin in the treatment of superficial suppurative skin and soft tissue infection. A double-blind study compared to amoxicillin. Japanese Journal of Antibiotics 1985;38(7):1794-818. x-wiley/crsRef/15497221
62. Geckler RW, Eng RH, Fabian TC, Echols RM, Jemsek JG, LeFrock JL. A multicenter comparative study of cefotetan once daily and cefoxitin thrice daily for the treatment of infections of the skin and superficial soft tissue. American Journal of Surgery 1988;155(5A):91-5. x-wiley/crsRef/15497223
63. Gentry LO, Rodriguez-Gomez G, Zeluff BJ, Khoshdel A, Price M. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. American Journal of Medicine 1989;87(6C):57S-60S. x-wiley/crsRef/15497225
64. Gentry LO, Ramirez-Ronda CH, Rodriguez-Noriega E, Thadepalli H, Del Rosal PL, Ramirez C. Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections. A multicenter trial. Archives of Internal Medicine 1989;149(11):2579-83. x-wiley/crsRef/15497227
65. Gentry LO, Rodriguez-Gomez G, Pien F, Cubeddu L, Holley HP Jr, Buaron K, et al. Comparative effects of ceftazidime two or three times daily in patients with skin and skin structure infections. American Journal of Therapeutics 1996;3(3):212-8. x-wiley/crsRef/15497229
66. Gesser RM, McCarroll KA, Woods GL. Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: Results of a double-blind clinical trial versus piperacillin-tazobactam. International Journal of Antimicrobial Agents 2004;23(3):235-9. x-wiley/crsRef/15497231
67. Gesser RM, McCarroll KA, Woods GL. Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. The Journal of Infection 2004;48(1):32-8. x-wiley/crsRef/15497233
68. Gordin FM, Wofsy CB, Mills J. Once-daily ceftriaxone for skin and soft tissue infections. Antimicrobial Agents & Chemotherapy 1985;27(4):648-9. x-wiley/crsRef/15497235
69. Gould IM, Hudson M, Morris J, Page G, Douglas JG, Smith CC, et al. Imipenem versus standard therapy in the treatment of serious soft tissue infection. Drugs Under Experimental & Clinical Research 1988;14(8):555-8. x-wiley/crsRef/15497237
70. Graham DR, Talan DA, Nichols RL, Lucasti C, Corrado M, Morgan N, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: A randomized, open-label trial. Clinical Infectious Diseases 2002;35(4):381-9. x-wiley/crsRef/15497239
71. Hanfling MJ, Hausinger SA, Squires J. Loracarbef vs. cefaclor in pediatric skin and skin structure infections. The Pediatric Infectious Disease Journal 1992;11(8 Suppl):S27-30. x-wiley/crsRef/15497241
72. Henry SA, Bendush CB. Aztreonam: Worldwide overview of the treatment of patients with gram-negative infections. American Journal of Medicine 1985;78(2a):57-64. x-wiley/crsRef/15497243
73. Hubsher JA, Gadebusch HH, Itkin AG. Double-blind comparison of cephradine and cephalexin in the treatment of skin and soft-tissue infections due to Staphylococcus aureus. Current Therapeutic Research, Clinical & Experimental 1976;19(6):579-88. x-wiley/crsRef/15497245
74. Jorup-Rönström C, Britton S, Gavlevik A, Gunnarsson K, Redman AC. The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas. Infection 1984;12(6):390-4. x-wiley/crsRef/15497247
75. Kulhanjian J, Dunphy MG, Hamstra S, Levernier K, Rankin M, Petru A, et al. Randomized comparative study of ampicillin/sulbactam vs. ceftriaxone for treatment of soft tissue and skeletal infections in children. The Pediatric Infectious Disease Journal 1989;8(9):605-10. x-wiley/crsRef/15497249
76. Lobo JM, Guedes MM. Treatment of bacterial skin infections. An open, randomized and comparative study among roxithromycin and cephalexin. Revista Brasileira de Medicina 1995;52(9):1047-51. x-wiley/crsRef/15497251
77. Miller LM, Mooney CJ, Hansbrough JF. Comparative evaluation of cefaclor versus cefadroxil in the treatment of skin and skin structure infections. Current Therapeutic Research, Clinical and Experimental 1989;46(3):405-10. x-wiley/crsRef/15497253
78. Nolen T, Conetta BJ, Durham SJ, Wilber RB. Safety and efficacy of cefprozil vs cefaclor in the treatment of mild to moderate skin and skin structure infections. Infections in Medicine 1992;9 Suppl C:56-68. x-wiley/crsRef/15497255
79. Parish LC, Parks DB, Layne PP, Uri JV. Ceftizoxime treatment of cutaneous and subcutaneous tissue infections. Clinical Therapeutics 1984;6(5):613-9. x-wiley/crsRef/15497257
80. Parish LC, Jungkind DL. Systemic antimicrobial therapy in skin and skin structure infections: Comparison of temafloxacin and ciprofloxacin. American Journal of Medicine 1991;91(6A):115S-9S. x-wiley/crsRef/15497259
81. Parish LC. Clarithromycin in the treatment of skin and skin structure infections: Two multicenter clinical studies. Clarithromycin Study Group. International Journal of Dermatology 1993;32(7):528-32. x-wiley/crsRef/15497261
82. Parish LC, Jungkind DL. Systemic antimicrobial therapy for skin and skin structure infections: Comparison of fleroxacin and ceftazidime. American Journal of Medicine 1993;94(3A):166S-73S. x-wiley/crsRef/15497263
83. Pereira LC. Comparative clinical study between roxithromycin and cephalexin in the treatment of folliculitis, furunculosis and Erysipelas /Cellulitis. Revista Brasileira De Medicina 1996;53(1-2):81-6. x-wiley/crsRef/15497265
84. Pérez-Ruvalcaba JA, Quintero-Pérez NP, Morales-Reyes JJ, Huitrón-Ramirez JA, Rodriguez-Chagollán JJ, Rodríguez-Noriega E. Double-blind comparison of ciprofloxacin with cefotaxime in the treatment of skin and skin structure infections. American Journal of Medicine 1987;82(4A):242-6. x-wiley/crsRef/15497267
85. Pien FD. Double-blind comparative study of two dosage regimens of cefaclor and amoxicillin-clavulanic acid in the outpatient treatment of soft tissue infections. Antimicrobial Agents & Chemotherapy 1983;24(6):856-9. x-wiley/crsRef/15497269
86. Ramírez-Ronda CH, Gutíerrez J, Bermúdez RH. Comparative effectiveness, safety and tolerance of mezlocillin and ticarcillin: A prospective randomized trial. Journal of Antimicrobial Chemotherapy 1982;9 Suppl A:125-9. x-wiley/crsRef/15497271
87. Ramirez-Ronda CH, Saavedra S, Rivera-Vázquez CR. Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections. American Journal of Medicine 1987;82(4A):220-3. x-wiley/crsRef/15497273
88. Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. International Journal of Infectious Diseases 2005;9(5):251-61. x-wiley/crsRef/15497275
89. Schupbach CW, Olovich KG, Dere WH. Efficacy of cefaclor AF in the treatment of skin and skin-structure infections. Clinical Therapeutics 1992;14(3):470-9. x-wiley/crsRef/15497277
90. Segev S, Rosen N, Pitlik SD, Block C, Rubinstein E. Pefloxacin versus ceftazidime in therapy of soft tissue infections in compromised patients. Journal of Antimicrobial Chemotherapy 1990;26 Suppl B:193-8. x-wiley/crsRef/15497279
91. Siami G, Christou N, Eiseman I, Tack KJ, Severe Skin and Soft Tissue Infections Study Group. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrobial Agents & Chemotherapy 2001;45(2):525-31. x-wiley/crsRef/15497281
92. Solomkin JS, Cocchetto DM. Ceftazidime versus tobramycin plus ticarcillin in the treatment of soft-tissue infections. Clinical Therapeutics 1986;9(1):123-34. x-wiley/crsRef/15497283
93. Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrobial Agents & Chemotherapy 2000;44(12):3408-13. x-wiley/crsRef/15497285
94. Tan JS, Wishnow RM, Talan DA, Duncanson FP, Norden CW. Treatment of hospitalized patients with complicated skin and skin structure infections: Double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group. Antimicrobial Agents and Chemotherapy 1993;37(8):1580-6. x-wiley/crsRef/15497287
95. Tassler H. Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infections. American Journal of Medicine 1993;94(3A):159S-65S. x-wiley/crsRef/15497289
96. Wasilewski MM, Wilson MG, Sides GD, Stotka JL. Comparative efficacy of 5 days of dirithromycin and 7 days of erythromycin in skin and soft tissue infections. Journal of Antimicrobial Chemotherapy 2000;46(2):255-62. x-wiley/crsRef/15497291
97. Wible K, Tregnaghi M, Bruss J, Fleishaker D, Naberhuis-Stehouwer S, Hilty M. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. The Pediatric Infectious Disease Journal 2003;22(4):315-23. x-wiley/crsRef/15497293
98. Chaudhary M, Shrivastava SM, Sehgal R. Efficacy and safety study of fixed-dose combination of ceftriaxone-vancomycin injection in patients with various infections. Current Drug Safety 2008;3(1):82-85. x-wiley/crsRef/15497295
99. Manaktala C, Singh AK, Verma M, Sachdeva A, Sharma H, Roy A, et al. Efficacy and tolerability of cefditoren pivoxil in uncomplicated skin and skin structure infections in Indian patients. Indian Journal of Dermatology 2009;54(4):350-6. x-wiley/crsRef/15497297
100. Nichols RL, Graham DR, Barriere SL, Rodgers A, Wilson SE, Zervos M, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Journal of Antimicrobial Chemotherapy 1999;44(2):263-273. x-wiley/crsRef/15497299
101. Noel GJ, Bush K, Bagchi P, Lanus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clinical Infectious Diseases 2008;46(5):647-655. x-wiley/crsRef/15497301
102. Pertel PE, Eisenstein BI, Link AS, Donfrid B, Biermann EJ, Bernardo P, et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. International Journal of Clinical Practice 2009;63(3):368-375. x-wiley/crsRef/15497303
103. Snodgrass WR, Anderson T. Prontosil in the treatment of erysipelas, a controlled series of 312 cases. British Medical Journal 1937;2(3993):101-104. x-wiley/crsRef/15497305
104. Snodgrass WR, Anderson T. Sulphanilamide in the treatment of erysipelas, a controlled series of 312 case. British Medical Journal 1937;2:1156-9. x-wiley/crsRef/15497307
105. Stein GE, Schooley SL, Havlichek DH, Nix DE. Outpatient intravenous antibiotic therapy compared with oral linezolid in patients with skin and soft tissue infections: A pharmacoeconomic analysis. Infectious Diseases in Clinical Practice 2008;16(4):235-239. x-wiley/crsRef/15497309
106. ISRCTN76443564. The efficacy and safety evaluation of ceftriaxone and sulbactam combination (1.5 gram) in patients with skin and soft tissue infections: An open label, parallel, randomized, prospective comparative trial. ISRCTN Register. x-wiley/crsRef/15497311
107. ® (Daptomycin for injection) with Vancomycin in the treatment of cellulitis or erysipelas. World Health Organisation International Clinical Trials Registry. x-wiley/crsRef/15497313
108. NCT00424190. Comparative study of ceftaroline vs. vancomycin plus aztreonam in adult subjects with complicated skin infections. ClinicalTrials.gov (accessed May 2010). x-wiley/crsRef/15497315
109. NCT00948142. Safety and efficacy of CEM-102 compared to linezolid in acute bacterial skin infections. ClinicalTrials.gov (accessed May 2010). x-wiley/crsRef/15497317
110. Altman DG, Schulz KF. Concealing treatment allocation in randomised trials. British Medical Journal 2001;323(7310):446-447.
111. Ambati BK, Ambati J, Azar N, Stratton L, Schmidt EV. Periorbital and orbital cellulitis before and after the advent of Haemophilus influenzae type B vaccination. Ophthalmology 2000;107(8):1450-1453.
112. Baddour LM, Bisno AL. Recurrent cellulitis after coronary bypass surgery. Association with superficial fungal infection in saphenous venectomy limbs. JAMA 1984;251(8):1049-52.
113. Bernard P, Toty L, Mounier M, Denis F, Bonnetblanc JM. Early detection of streptococcal group antigens in skin samples by latex particle agglutination. Archives of Dermatology 1987;123(4):468-70.
114. British Lymphology Society. Consensus Document on the Management of Cellulitis in Lymphoedema. www.lymphoedema.org/lsn/ (accessed July 2007).
115. Brook I, Frazier EH. Clinical features and aerobic and anaerobic microbiological characteristics of cellulitis. Archives of Surgery (Chicago, Ill.: 1960) 1995;130(7):786-92.
116. Carter K, Kilburn S, Featherstone P. Cellulitis and treatment: A qualitative study of experiences. British Journal of Nursing 2007;16(6):S22-4, S26-8.
117. Chan R, Hemeryck L, O'Regan M, Clancy L, Feely J. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: Open, randomised controlled trial. BMJ 1995;310(6991):1360-2.
118. Corwin P, Toop L, McGeoch G, Than M, Wynn-Thomas S, Wells JE, et al. Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. BMJ 2005;330(7483):129-32.
119. Cox NH, Colver GB, Paterson WD. Management and morbidity of cellulitis of the leg. Journal of the Royal Society of Medicine 1998;91(12):634-7.
120. Cox MH. Oedema as a risk factor for multiple episodes of cellulitis/erysipelas of the lower leg: A series with community follow-up. British Journal of Dermatology 2006;155(5):947-50.
121. Clinical Resource Efficiency Support Team (CREST). Guidelines on the management of cellulitis in adults. http//www.crestni.org.uk 2005. [ISBN 1-903982-12-X]
122. Critchley G, Handa A, Maw A, Harvey A, Harvey MR, Corbett CR. Complications of varicose vein surgery. Annals of the Royal College of Surgeons of England 1997;79(2):105-10.
123. Dupuy A, Benchikhi H, Roujeau JC, Bernard P, Vaillant L, Chosidow O, et al. Risk factors for erysipelas of the leg (cellulitis): Case-control study. BMJ 1999;318(7198):1591-4.
124. Ellis Simonsen SM, Van Orman ER, Hatch BE, Jones SS, Gren LH, Hegann KT, et al. Cellulitis incidence in a defined population. Epidemiology and Infection 2006;134(2):293-9.
125. Eriksson B, Jorup-Rönström C, Karkkonen K, Sjöblom AC, Holm SE. Erysipelas: Clinical and bacteriologic spectrum and serological aspects. Clinical Infectious Diseases 1996;23(5):1091-8.
126. Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA, et al. Managing skin and soft tissue infections: Expert panel recommendations on key decision points. Journal of Antimicrobial Chemotherapy 2003;52 Suppl 1:i3-17.
127. Escalante A, Beardmore TD. Risk factors for early wound complications after orthopedic surgery for rheumatoid arthritis. The Journal of Rheumatology 1995;22(10):1844-51.
128. Haan MN, Selby JV, Quesenberry CP Jr, Schmittdiel JA, Fireman BH, Rice DP. The impact of ageing and chronic disease on use of hospital and outpatient services in a large HMO: 1971-1991. Journal of the American Geriatrics Society 1997;45(6):667-74.
129. Hay RJ, Adriaans BM. Bacterial Infections. In: Burns DA, Breathnach SM, Cox NH, Griffiths CEM, editors(s). Rook's Textbook of Dermatology. 7th edition. Vol. 1. Oxford: Blackwell Publishing, 2004:27.16-27.20.
130. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2008.
131. Hoberman A, Wald ER, Hicky RW, Baskin M, Charron M, Masoud M, et al. Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 1999;104:79-86.
132. Jorup-Rönström C, Britton S. Recurrent erysipelas: Predisposing factors and costs of prophylaxis. Infection 1987;15(2):105-6.
133. Jüni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
134. Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. New England Journal of Medicine 1999;341(5):312-8. [MEDLINE: 10423465]
135. Kluytmans-Vandenbergh MF, Kluytmans JA. Community-acquired methicillin-resistant Staphylococcus aureus: Current perspectives. Clinical Microbiology and Infection 2006;12 Suppl 1:9-15.
136. Lasley DS, Eblen A, Yancey MK, Duff P. The effect of placental removal method on the incidence of postcesarean infections. American Journal of Obstetrics & Gynecology 1997;176(6):1250-4.
137. Mokni M, Dupuy A, Denguezli M, Dhaoui R, Bouassida S, Amri M, et al. Risk factors for erysipelas of the leg in Tunisia: A multicenter case-control study. Dermatology 2006;212(2):108-12.
138. Morris A. Cellulitis and Erysipelas. In: BMJ editorial board, editors(s). Clinical Evidence. London: BMJ Books, 2001:1146-9.
139. ISRCTN34716921 (PATCH I), ISRCTN03813200 (PATCH II), UKDCTN0501. Randomised controlled trials to investigate whether prophylactic antibiotics can prevent further episodes of cellulitis (erysipelas) of the leg. clinicaltrials.gov.
140. Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: Risk factors. Journal der Deutschen Dermatologischen Gesellschaft 2004;2(2):89-95.
141. Purcell K, Fergie J. Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: A 14-year study at Driscoll Children's Hospital. Archives of Pediatrics & Adolescent Medicine 2005;159(10):980-85.
142. Rojas MX, Granados C. Oral antibiotics versus parenteral antibiotics for severe pneumonia in children. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No: CD004979. [DOI: 10.1002/14651858.CD004979.pub2]
143. Roujeau JC, Sigurgeirsson B, Korting HC, Kerl H, Paul C. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: A case-control study. Dermatology 2004;209(4):301-7.
144. Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMJ Publishing Group Ltd and RPS Publishing, 2007.
145. Societe Francaise de Dermatologie. Erysipelas and necrotizing fasciitis [Erysipele et fasiite necrosante: prise en charge]. Annales de dermatologie et de vénéréologie 2001;128:463-82.
146. Soo J K, Bicanic T A, Heenan S, Mortimer P S. Lymphatic abnormalities demonstrated by lymphoscintigraphy after lower limb cellulitis. British Journal of Dermatology 2008;158(6):1350-53.
147. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clinical Infectious Diseases 2005;41(10):1373-406.
148. Thomas TA, Taylor SM, Crane MM, Cornett WR, Langan EM 3rd, Snyder BA, et al. An analysis of limb-threatening lower extremity wound complications after 1090 consecutive coronary artery bypass procedures. Vascular medicine (London, England) 1999;4(2):83-8.
149. United Kingdom Department of Health. Hospital Episode Statistics 2001. www.statistics.gov.uk (accessed June 2003).